Both RPPA and Western blotting analysis revealed that BCL-2 maintains robust expression after MCPyV-positive MCC cell lines were treated with glaucarubin (Figure 3 and Figure 5, and Figure S4), indicating that even in the cell lines where p53 is activated, it is not sufficient to reduce the BCL-2 level (Figure 6B). The gene discussed is TP53; the disease is Merkel cell skin cancer.